Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. Plasma-derived vaccine in children : immunogenicity and anamnestic responses.
In a prospective randomized trial, 918 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-mug doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 mo (group 1), three 5-mug doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and B mo (group 2) or three 10-mug doses of plasma-derived hepatitis B vaccine (group 9).
The HBs antibody response rate at 8 mo was between 93% and 99%; it was still 75% to 87% at 5 yr in all three groups.
Geometric mean titers at 1 yr were 89, 1,085 and 858 mIU/ml in groups 1, 2 and 9, respectively.
Mots-clés Pascal : Virus hépatite B, Hepadnaviridae, Virus, Etude comparative, Toxicité, Hépatite virale B, Virose, Infection, Immunoprophylaxie, Prévention, Immunogénicité, Enfant, Homme, DNA recombinant, Hong Kong, Asie, Vaccin, Réponse immune, Immunité humorale, Foie pathologie, Appareil digestif pathologie
Mots-clés Pascal anglais : Hepatitis B virus, Hepadnaviridae, Virus, Comparative study, Toxicity, Viral hepatitis B, Viral disease, Infection, Immunoprophylaxis, Prevention, Immunogenicity, Child, Human, Recombinant DNA, Hong Kong, Asia, Vaccine, Immune response, Humoral immunity, Hepatic disease, Digestive diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0088272
Code Inist : 002B05C02G. Création : 199406.